Top

Current Hepatology Reports

Published in:

11-03-2024 | Acute Kidney Injury | Review

Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?

Authors: Satender Pal Singh, Tushar Madke, Rakhi Maiwall

Published in: Current Hepatology Reports | Issue 2/2024

Abstract

Purpose of Review

Hepatorenal syndrome (HRS), the severe manifestation of renal injury in patients with cirrhosis and acute on chronic liver failure (ACLF), is characterized by decreased renal blood flow and glomerular filtration rate. Manuscript will elaborate how acute kidney injury (AKI) is different in ACLF and cirrhosis.

Recent Findings

We have role of biomarkers in differentiating HRS AKI from chronic kidney disease (CKD) in cirrhosis as well as ACLF patients. Medical therapy, timing of extracorporeal therapies, and role of liver transplant in patients of cirrhosis and ACLF.

Summary

ACLF patients usually have structural form of AKI as compared to functional-volume responsive AKI in patients with cirrhosis. Combination of terlipressin and albumin augments renal recovery faster than other vasopressor therapies. But, liver transplant always remain the definitive treatment of progressive renal failure in patients with cirrhosis as well as ACLF.

•• Maiwall R, Kumar S, Chandel SS, et al. AKI in patients with acute on chronic liver failure is different from acute decompensation of cirrhosis. Hepatol Int. 2015;9(4):627–39. https://doi.org/10.1007/s12072-015-9653-x. This reference shows that AKI in ACLF has structural component and early detection and timely management is necessary.CrossRefPubMed

Khatua CR, Panigrahi S, Mishra D, et al. Acute kidney injury at admission is a better predictor of mortality than its persistence at 48 h in patients with acute-on-chronic liver failure. J Clin Transl Hepatol. 2018;6(4):396–401.https://doi.org/10.14218/JCTH.2018.00035CrossRefPubMedPubMedCentral

Lafrance JP, Miller DR. Acute kidney injury associates with increased long-term mortality. J Am Soc Nephrol. 2010;21(2):345–52. https://doi.org/10.1681/ASN.2009060636.CrossRefPubMedPubMedCentral

Boima V. Creatinine based equations and glomerular filtration rate: interpretation and clinical relevance. Ghana Med J. 2016;50(3):119–21.CrossRefPubMedPubMedCentral

Lopes JA, Jorge S. The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review. Clin Kidney J. 2013;6(1):8–14.CrossRefPubMed

Kim JH, Kim YS, Choi MS, et al. Prediction of clinical outcomes after kidney transplantation from deceased donors with acute kidney injury: a comparison of the KDIGO and AKIN criteria. BMC Nephrol. 2017;18(1):39. https://doi.org/10.1186/s12882-017-0461-5.CrossRefPubMedPubMedCentral

Amathieu R, Al-Khafaji A, Sileanu FE, et al. Significance of oliguria in critically ill patients with chronic liver disease. Hepatology. 2017;66(5):1592–600. https://doi.org/10.1002/hep.29303.CrossRefPubMed

Maiwall R, Pasupuleti SSR, Chandel SS, et al. Co-orchestration of acute kidney injury and non-kidney organ failures in critically ill patients with cirrhosis. Liver Int. 2021;41(6):1358–69. https://doi.org/10.1111/liv.14809.CrossRefPubMed

Tonon M, Rosi S, Gambino CG, et al. Natural history of acute kidney disease in patients with cirrhosis. J Hepatol. 2021;74(3):578–83. https://doi.org/10.1016/j.jhep.2020.08.037.CrossRefPubMed

10.

Napoleone L, Solé C, Juanola A, et al. Patterns of kidney dysfunction in acute-on-chronic liver failure: relationship with kidney and patients’ outcome. Hepatol Commun. 2022;6(8):2121–31.CrossRefPubMedPubMedCentral

11.

•• Bassegoda O, Huelin P, Ariza X, et al. Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol. 2020;72(6):1132–9. https://doi.org/10.1016/j.jhep.2019.12.020. This reference shows spectrum of AKI and natural history of progression to CKD.CrossRefPubMed

12.

• Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811–22. https://doi.org/10.1016/j.jhep.2019.07.002. This reference provides existing guidelines for AKI in patients of cirrhosis.CrossRefPubMed

13.

Jiang QQ, Han MF, Ma K, et al. Acute kidney injury in acute-on-chronic liver failure is different from in decompensated cirrhosis. World J Gastroenterol. 2018;24(21):2300–10. https://doi.org/10.3748/wjg.v24.i21.2300.CrossRefPubMedPubMedCentral

14.

CANONIC Study Investigators of the EASL-CLIF Consortium and the European Foundation for the Study of Chronic Liver Failure (EF-CLIF), Clària J, Stauber RE, Coenraad MJ, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64:1249–64.CrossRef

15.

Investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif), Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74:670–85.CrossRef

16.

Choudhury A, Kumar M, Sharma BC, et al. APASL ACLF working party. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of ‘golden window’: a prospective study. J Gastroenterol Hepatol. 2017;32:1989–97.CrossRefPubMed

17.

CANONIC Study Investigators of the EASL Clif Consortium; Grifols Chair European Foundation for the Study of Chronic Liver Failure (EF Clif), Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2020;72:688–701.CrossRef

18.

Zaccherini G, Aguilar F, Caraceni P, et al. Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. J Hepatol. 2021;74:1117–31.CrossRefPubMed

19.

CANONIC Study Investigators of the EASL Clif Consortium, Grifols Chair and the European Foundation for the Study of Chronic Liver Failure (EF Clif), Clària J, Moreau R, Fenaille F, et al. Orchestration of tryptophan-kynurenine pathway, acute decompensation, and acute-on-chronic liver failure in cirrhosis. Hepatology. 2019;69:1686–701.CrossRef

20.

Fickert P, Rosenkranz AR. Cholemic nephropathy reloaded. Semin Liver Dis. 2020;40:91–100.CrossRefPubMed

21.

Bräsen JH, Mederacke YS, Schmitz J, et al. Cholemic nephropathy causes acute kidney injury and is accompanied by loss of aquaporin 2 in collecting ducts. Hepatology. 2019;69:2107–19.CrossRefPubMed

22.

Morales-Alvarez MC. Nephrotoxicity of antimicrobials and antibiotics. Adv Chronic Kidney Dis. 2020;27:31–7.CrossRefPubMed

23.

Patschan D, Patschan S, Buschmann I, et al. Loop diuretics in acute kidney injury prevention, therapy, and risk stratification. Kidney Blood Press Res. 2019;44:457–64.CrossRefPubMed

24.

Sadat U. Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategies. ISRN Radiol. 2013;16(2013):496438. https://doi.org/10.5402/2013/496438.CrossRef

25.

Zang H, Liu F, Liu H, et al. Incidence, risk factors and outcomes of acute kidney injury (AKI) in patients with acute-on-chronic liver failure (ACLF) of underlying cirrhosis. Hepatol Int. 2016;10:807–18.CrossRefPubMed

26.

Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic Liver Failure. Hepatology. 2020;72(3):1043–55. https://doi.org/10.1002/hep.31071.CrossRefPubMed

27.

• Singh SP, Maiwall R. MELD 3.0: A better score for liver allocation? Liver Transpl. 2023:. https://doi.org/10.1097/LVT.0000000000000180. This reference gives update about the serum creatinine and AKI in MELD, MELD NA, MELD 3.0.

28.

Solé C, Ma AT, Solà E, et al. Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver Int. 2021;41(11):2729–32. https://doi.org/10.1111/liv.15069.CrossRefPubMed

29.

Markwardt D, Holdt L, Steib C, et al. Plasma cystatin C is a predictor of renal dysfunction, acute-on-chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis. Hepatology. 2017;66:1232–41.CrossRefPubMed

30.

Maiwall R, Kumar A, Bhardwaj A, et al. Cystatin C predicts acute kidney injury and mortality in cirrhotics: a prospective cohort study. Liver Int. 2018;38(4):654–64. https://doi.org/10.1111/liv.13600.CrossRefPubMed

31.

Wan ZH, Wang JJ, You SL, et al. Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure. World J Gastroenterol. 2013;19(48):9432–8. https://doi.org/10.3748/wjg.v19.i48.9432.CrossRefPubMedPubMedCentral

32.

Lu J, Lin L, Ye C, et al. Serum NGAL is superior to cystatin C in predicting the prognosis of acute-on-chronic liver failure. Ann Hepatol. 2019;18(1):155–64. https://doi.org/10.5604/01.3001.0012.7907.CrossRefPubMed

33.

Lei L, Li LP, Zeng Z, et al. Value of urinary KIM-1 and NGAL combined with serum Cys C for predicting acute kidney injury secondary to decompensated cirrhosis. Sci Rep. 2018;8(1):7962. https://doi.org/10.1038/s41598-018-26226-6.CrossRefPubMedPubMedCentral

34.

CANONIC Investigators, EASL CLIF Consortium, Ariza X, Graupera I, Coll M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016;65(1):57–65.CrossRef

35.

Kulkarni AV, Sharma M, Kumar P, et al. Adipocyte fatty acid-binding protein as a predictor of outcome in alcohol-induced acute-on-chronic liver failure. J Clin Exp Hepatol. 2021;11(2):201–8. https://doi.org/10.1016/j.jceh.2020.07.010.CrossRefPubMed

36.

Levitsky J, Baker TB, Jie C, et al. Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology. 2014;60(6):2017–26. https://doi.org/10.1002/hep.27346.CrossRefPubMed

37.

Levitsky J, Asrani SK, Abecassis M, et al. External Validation of a Pretransplant Biomarker Model (REVERSE) Predictive of renal recovery after liver transplantation. Hepatology. 2019;70(4):1349–59. https://doi.org/10.1002/hep.30667.CrossRefPubMed

38.

Maiwall R, Pasupuleti SSR, Hidam AK, et al. Non-resolution of acute kidney injury in the first week portends the development of chronic kidney disease in critically ill patients with cirrhosis. Aliment Pharmacol Ther. 2023: https://doi.org/10.1111/apt.17639

39.

Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic. Nephrol Ther. 2016;12(Suppl 1(Suppl 1)):S41–8. https://doi.org/10.1016/j.nephro.2016.02.005.CrossRefPubMedPubMedCentral

40.

Campion D, Rizzi F, Bonetto S, et al. Assessment of glomerular filtration rate in patients with cirrhosis: available tools and perspectives. Liver Int. 2022;42(11):2360–76. https://doi.org/10.1111/liv.15198.CrossRefPubMed

41.

Malbrain MLNG, Van Regenmortel N, Saugel B, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;22(8):66.CrossRef

42.

Rice JA, Brewer J, Speaks T, Choi C, Lahsaei P, Romito BT. The POCUS consult: how point of care ultrasound helps guide medical decision making. Int J Gen Med. 2021;14:9789–806. https://doi.org/10.2147/IJGM.S339476.CrossRefPubMedPubMedCentral

43.

REVERSE-AKI study team, Vaara ST, Ostermann M, Bitker L, et al. Restrictive fluid management versus usual care in acute kidney injury (REVERSE-AKI): a pilot randomized controlled feasibility trial. Intensive Care Med. 2021;47:665–73. https://doi.org/10.1007/s00134-021-06401-6.CrossRef

44.

National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564–75. https://doi.org/10.1056/NEJMoa062200.CrossRef

45.

REVERSE Study Investigators, Boyer TD, Sanyal AJ, Wong F, et al. Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1. Gastroenterology. 2016;150(7):1579-1589.e2. https://doi.org/10.1053/j.gastro.2016.02.026.CrossRef

46.

•• Arora V, Maiwall R, Rajan V. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure. Hepatology. 2020;71:600–10. This is only well designed study showing performance of terlipressin is better than noradrenaline in patients with ACLF.CrossRefPubMed

47.

Alessandria C, Ottobrelli A, Debernardi-Venon W, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499–505. https://doi.org/10.1016/j.jhep.2007.04.010.CrossRefPubMed

48.

Singh V, Ghosh S, Singh B, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293–8. https://doi.org/10.1016/j.jhep.2012.01.012.CrossRefPubMed

49.

Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome, Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62(2):567–74. https://doi.org/10.1002/hep.27709.CrossRef

50.

Esrailian E, Pantangco ER, Kyulo NL, et al. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome. Dig Dis Sci. 2007;52(3):742–8. https://doi.org/10.1007/s10620-006-9312-0.CrossRefPubMed

51.

Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol. 2003;18(2):152–6. https://doi.org/10.1046/j.1440-1746.2003.02934.x.CrossRefPubMed

52.

Terlipressin Study Group, Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008;134(5):1360–8. https://doi.org/10.1053/j.gastro.2008.02.014.CrossRef

53.

ANSWER Study Investigators, Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391(10138):2417–29. https://doi.org/10.1016/S0140-6736(18)30840-7.CrossRef

54.

CONFIRM Study Investigators, Wong F, Pappas SC, Curry MP, et al. Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome. N Engl J Med. 2021;384(9):818–28. https://doi.org/10.1056/NEJMoa2008290.CrossRef

55.

ATTIRE Trial Investigators, China L, Freemantle N, Forrest E, et al. A randomized trial of albumin Infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808–17. https://doi.org/10.1056/NEJMoa2022166.CrossRef

56.

Solà E, Solé C, Simón-Talero M, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J Hepatol. 2018;69(6):1250–9. https://doi.org/10.1016/j.jhep.2018.08.006.CrossRefPubMed

57.

Lin WT, Lai CC, Chang SP, Wang JJ. Effects of early dialysis on the outcomes of critically ill patients with acute kidney injury: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2019;9(1):18283.CrossRefPubMedPubMedCentral

58.

Saraiva IE, Ortiz-Soriano VM, Mei X, et al. Continuous renal replacement therapy in critically ill patients with acute on chronic liver failure and acute kidney injury: a retrospective cohort study. Clin Nephrol. 2020;93(4):187–94. https://doi.org/10.5414/CN109983.CrossRefPubMed

59.

Zarbock A, Kellum JA, Schmidt C, et al. Effect of early vs delayed initiation of renal replacement therapy on mortality in critically Ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA. 2016;315(20):2190–9. https://doi.org/10.1001/jama.2016.5828.CrossRefPubMed

60.

Zhang S, Suen SC, Gong CL, et al. Early transplantation maximizes survival in severe acute-on-chronic liver failure: results of a Markov decision process model. JHEP Rep. 2021;23(3):100367.CrossRef

61.

Goussous N, Xie W, Zhang T, et al. Acute on chronic liver failure: factors associated with transplantation. Transplant Direct. 2021;7(12):e788.CrossRefPubMedPubMedCentral

62.

Sundaram V, Jalan R, Wu T, et al. Factors associated with survival of patients with severe acute-on-chronic liver failure before and after liver transplantation. Gastroenterology. 2019;156:1381-1391.e3.CrossRefPubMed

63.

Goosmann L, Buchholz A, Bangert K, et al. Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. Liver Int. 2021;41:574–84.CrossRefPubMed

64.

Singh SP, Jindal A. Association of rectal colonisation by MDROs with new infection in cirrhosis. J Hepatol. 2022;77(2):577–8. https://doi.org/10.1016/j.jhep.2022.03.001.CrossRefPubMed

Title: Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?
Authors: Satender Pal Singh
Tushar Madke
Rakhi Maiwall
Publication date: 11-03-2024
Publisher: Springer US
Keywords: Acute Kidney Injury
Acute Kidney Injury
Hepatorenal Syndrome
Hepatorenal Syndrome
Chronic Kidney Disease
Published in: Current Hepatology Reports / Issue 2/2024
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-024-00660-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2024

Expanding the Donor Pool for Liver Transplantation: Assessing the Potential Use of HBV-Positive Allografts

Treatment of Gastric Varices

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Hepatitis B Virus Elimination Strategies

Management of Hepatitis B in Pregnancy

When to Stop Antiviral Therapy in HBeAg-Negative Patients with Chronic Hepatitis B?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage